These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25982669)

  • 1. Evaluation of the safety and efficacy of TY-51924 in patients with ST elevated acute myocardial infarction - Early phase II first in patient pilot study.
    Takayama T; Kimura K; Fukuzawa S; Hirayama H; Sone T; Ueda Y; Uematsu M; Ishihara M; Nakao K; Matsumoto N; Kosuge M; Hiro T; Asakura M; Kaneko A; Yokoi T; Hirayama A
    J Cardiol; 2016 Feb; 67(2):162-9. PubMed ID: 25982669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial of TY-51924, a novel hydrophilic NHE inhibitor, in acute myocardial infarction.
    Kimura K; Nakao K; Shibata Y; Sone T; Takayama T; Fukuzawa S; Nakama Y; Hirayama H; Matsumoto N; Kosuge M; Hiro T; Sakuma H; Ishihara M; Asakura M; Hamada C; Kaneko A; Yokoi T; Hirayama A;
    J Cardiol; 2016 Apr; 67(4):307-13. PubMed ID: 26359711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial design and rationale of TY-51924 as a novel Na+/H+ exchanger inhibitor in patients with ST-elevation acute myocardial infarction undergoing percutaneous coronary intervention.
    Ishihara M; Asakura M; Kimura K; Nakao K; Hamada C; Hirayama A
    J Cardiol; 2014 Jan; 63(1):82-7. PubMed ID: 23860273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cardioprotective effects of novel Na+/H+ exchanger inhibitor TY-51924 on ischemia/reperfusion injury.
    Sasamori J; Hasegawa T; Takaya A; Watanabe Y; Tanaka M; Ogino Y; Chiba T; Aihara K
    J Cardiovasc Pharmacol; 2014 Apr; 63(4):351-9. PubMed ID: 24336011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial.
    Zeymer U; Suryapranata H; Monassier JP; Opolski G; Davies J; Rasmanis G; Linssen G; Tebbe U; Schröder R; Tiemann R; Machnig T; Neuhaus KL;
    J Am Coll Cardiol; 2001 Nov; 38(6):1644-50. PubMed ID: 11704395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study.
    Jang IK; Pettigrew V; Picard MH; Kowey PR; Demmel V; Zile MR; Tatsuno J; Wackers FJ; Hibberd M
    J Thromb Thrombolysis; 2005 Dec; 20(3):147-53. PubMed ID: 16261287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial.
    Ibanez B; Macaya C; Sánchez-Brunete V; Pizarro G; Fernández-Friera L; Mateos A; Fernández-Ortiz A; García-Ruiz JM; García-Álvarez A; Iñiguez A; Jiménez-Borreguero J; López-Romero P; Fernández-Jiménez R; Goicolea J; Ruiz-Mateos B; Bastante T; Arias M; Iglesias-Vázquez JA; Rodriguez MD; Escalera N; Acebal C; Cabrera JA; Valenciano J; Pérez de Prado A; Fernández-Campos MJ; Casado I; García-Rubira JC; García-Prieto J; Sanz-Rosa D; Cuellas C; Hernández-Antolín R; Albarrán A; Fernández-Vázquez F; de la Torre-Hernández JM; Pocock S; Sanz G; Fuster V
    Circulation; 2013 Oct; 128(14):1495-503. PubMed ID: 24002794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardioprotective effect of TY-12533, a novel Na(+)/H(+) exchange inhibitor, on ischemia/reperfusion injury.
    Aihara K; Hisa H; Sato T; Yoneyama F; Sasamori J; Yamaguchi F; Yoneyama S; Mizuno Y; Takahashi A; Nagai A; Kimura T; Kogi K; Satoh S
    Eur J Pharmacol; 2000 Sep; 404(1-2):221-9. PubMed ID: 10980282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GUARD During Ischemia Against Necrosis (GUARDIAN) trial in acute coronary syndromes.
    Erhardt LR
    Am J Cardiol; 1999 May; 83(10A):23G-25G. PubMed ID: 10482177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
    Jang IK; Weissman NJ; Picard MH; Zile MR; Pettigrew V; Shen S; Tatsuno J; Hibberd MG; Tzivoni D; Wackers FJ;
    Am Heart J; 2008 Jan; 155(1):113.e1-8. PubMed ID: 18082500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the Na(+)/H(+) exchanger confers greater cardioprotection against 90 minutes of myocardial ischemia than ischemic preconditioning in dogs.
    Gumina RJ; Buerger E; Eickmeier C; Moore J; Daemmgen J; Gross GJ
    Circulation; 1999 Dec 21-28; 100(25):2519-26; discussion 2469-72. PubMed ID: 10604890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
    Berger JS; Roe MT; Gibson CM; Kilaru R; Green CL; Melton L; Blankenship JD; Metzger DC; Granger CB; Gretler DD; Grines CL; Huber K; Zeymer U; Buszman P; Harrington RA; Armstrong PW
    Am Heart J; 2009 Dec; 158(6):998-1004.e1. PubMed ID: 19958867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial.
    Crimi G; Pica S; Raineri C; Bramucci E; De Ferrari GM; Klersy C; Ferlini M; Marinoni B; Repetto A; Romeo M; Rosti V; Massa M; Raisaro A; Leonardi S; Rubartelli P; Oltrona Visconti L; Ferrario M
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1055-63. PubMed ID: 24156966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction - a pilot study.
    Chitose T; Sugiyama S; Sakamoto K; Shimomura H; Yamashita T; Hokamaki J; Tsunoda R; Shiraishi S; Yamashita Y; Ogawa H
    Atherosclerosis; 2014 Nov; 237(1):251-8. PubMed ID: 25262434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion.
    Buerke M; Rupprecht HJ; vom Dahl J; Terres W; Seyfarth M; Schultheiss HP; Richardt G; Sheehan FH; Drexler H
    Am J Cardiol; 1999 May; 83(10A):19G-22G. PubMed ID: 10482176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and rationale of low-dose erythropoietin in patients with ST-segment elevation myocardial infarction (EPO-AMI-II study): a randomized controlled clinical trial.
    Minamino T; Toba K; Higo S; Nakatani D; Hikoso S; Umegaki M; Yamamoto K; Sawa Y; Aizawa Y; Komuro I;
    Cardiovasc Drugs Ther; 2012 Oct; 26(5):409-16. PubMed ID: 22940818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of Early Treatment With Melatonin to Reduce Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction Receiving Percutaneous Coronary Intervention (From the Melatonin Adjunct in the Acute Myocardial Infarction Treated With Angioplasty Trial).
    Dominguez-Rodriguez A; Abreu-Gonzalez P; de la Torre-Hernandez JM; Consuegra-Sanchez L; Piccolo R; Gonzalez-Gonzalez J; Garcia-Camarero T; Del Mar Garcia-Saiz M; Aldea-Perona A; Reiter RJ;
    Am J Cardiol; 2017 Aug; 120(4):522-526. PubMed ID: 28645475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of the 'MITOCARE' Study: a phase II, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRO40303 for the reduction of reperfusion injury in patients undergoing percutaneous coronary intervention for acute myocardial infarction.
    MITOCARE Study Group
    Cardiology; 2012; 123(4):201-7. PubMed ID: 23202613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The myocardial Na+/H+ exchanger: a potential therapeutic target for the prevention of myocardial ischaemic and reperfusion injury and attenuation of postinfarction heart failure.
    Karmazyn M; Sostaric JV; Gan XT
    Drugs; 2001; 61(3):375-89. PubMed ID: 11293648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin in ST-elevation myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging.
    Fuernau G; Zaehringer S; Eitel I; de Waha S; Droppa M; Desch S; Schuler G; Adams V; Thiele H
    Int J Cardiol; 2013 Sep; 167(5):2134-9. PubMed ID: 22704876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.